About Evotec
Evotec is a life science company driving the discovery and development of highly effective therapeutics through world-class science and technology platforms. By combining cutting-edge research capabilities with deep expertise across multiple therapeutic areas, Evotec partners with pharmaceutical, biotechnology, and academic organizations worldwide to accelerate the development of innovative medicines for patients.
The EVP Global Head of Drug Discovery Platforms is a strategic and operational executive leadership role responsible for defining and executing Evotec’s global platform strategy across Hit Identification, QPS, Sample Management, Discovery Biopharmaceutics, OMICs, and ADMETox/Cyprotex capabilities. The role leads a global organisation of approximately 900 FTE across five countries and is accountable for scientific excellence, operational performance, commercial growth, innovation, and financial results. As a key member of the Drug Discovery leadership team, the incumbent drives industrial-scale platform delivery, technology advancement, automation, digitalisation, AI-enabled innovation, and strategic partnerships while ensuring seamless integration across the drug discovery and development continuum.
Responsibilities
Set the strategic and scientific direction for Evotec’s global Drug Discovery Platforms function, with a clear technology roadmap across all platform domains.
Lead a highly efficient global Hit Identification platform, covering assay development, ultra-high-throughput screening (uHTS), high-content imaging (HCI), automated patch clamp (APC) and other medium-throughput screening, hit triaging, validation and expansion, screening collection development, in silico hit identification, and genome-wide screening approaches (wet and virtual).
Lead QPS, covering recombinant reagent design and production, cell line compliance, development and banking, biophysics method development and analysis across all modalities (centralised for efficiency, co-located for turnaround), structural biology to focus drug design across all modalities, and RNA production and hit finding.
Lead end-to-end Sample Management for small molecules and biosamples, with large and scalable capacity for long-term sample storage, focused on pharma, biotech and other industrial partners.
Lead Discovery Biopharmaceutics, covering formulation, PhysChem, solid-state, quantitative bioanalysis and metabolite identification, and in vivo rodent and higher-species PK, with growing experience across an expanding range of modalities and efficiency improvements such as centralisation of rodent PK.
Lead OMICs data generation platforms, including genomics, transcriptomics, proteomics and metabolomics, covering sample preparation through to the processing of raw data, targeted proteomics by mass spectrometry, non-targeted proteomics by non-MS readouts (affinity-based, protein sequencing and similar), and human sample management and OMICs data generation to support Evotec’s Molecular Patient Database (E.MPD).
Lead the integrated Cyprotex ADMETox capability, formed from the combination of Discovery DMPK, Discovery Safety and Cyprotex, as both an enabler of integrated projects and an entry point for bespoke standalone projects and high-volume, highly automated screening.
Deliver a best-in-class CRO experience for high-volume routine ADMETox screening through industrialised automation.
Develop a world-leading in vitro predictive safety product line as a NAMs (New Approach Methodologies) Centre of Excellence, complementing NAMs with in silico, AI and ML tools to enhance the predictability of clinical outcomes.
Provide scientific leadership in Discovery Safety through Target Safety Assessment (TSA) generation, provision of project representatives and cascade design, with an integrated mix of wet-lab data, dry-lab modelling and drug-hunting input.
Expand partnerships through collaborative development of bespoke and novel solutions, with applications…